Mycobacterium tuberculosis GroEL2 Modulates Dendritic Cell Responses

Maria Georgieva,a* Jonathan Kevin Sia,a Erica Bizzell,a Ranjna Madan-Lala,a Jyothi Rengarajan,a,b

aEmory Vaccine Center, Emory University, Atlanta, Georgia, USA
bDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

ABSTRACT Mycobacterium tuberculosis successfully subverts the host immune response to promote disease progression. In addition to its known intracellular niche in macrophages, M. tuberculosis interferes with the functions of dendritic cells (DCs), which are the primary antigen-presenting cells of the immune system. We previously showed that M. tuberculosis dampens proinflammatory responses and impairs DC functions through the cell envelope-associated serine protease Hip1. Here we present data showing that M. tuberculosis GroEL2, a substrate of Hip1, modulates DC functions. The full-length GroEL2 protein elicited robust proinflammatory responses from DCs and promoted DC maturation and antigen presentation to T cells. In contrast, the cleaved form of GroEL2, which predominates in M. tuberculosis, was poorly immunostimulatory and was unable to promote DC maturation and antigen presentation. Moreover, DCs exposed to full-length, but not cleaved, GroEL2 induced strong antigen-specific gamma interferon (IFN-γ), interleukin-2 (IL-2), and IL-17A cytokine responses from CD4+ T cells. Moreover, the expression of cleaved GroEL2 in the hip1 mutant restored the robust T cell responses to wild-type levels, suggesting that proteolytic cleavage of GroEL2 allows M. tuberculosis to prevent optimal DC-T cell cross talk during M. tuberculosis infection.

KEYWORDS Mycobacterium tuberculosis, dendritic cells

M. tuberculosis is a highly successful human pathogen that has evolved multiple mechanisms to evade and manipulate host innate and adaptive immunity (1–3). While CD4+ T cell responses are important for mycobacterial control, M. tuberculosis delays the onset of antigen-specific T cell responses, which are unable to effectively eliminate the pathogen from infected hosts. These suboptimal CD4+ T cell responses are in part due to the ability of M. tuberculosis to impair dendritic cell (DC) functions such as the migration of infected DCs from the lung to draining lymph nodes, DC maturation, and antigen presentation to naive CD4+ T cells (4–6). As the primary antigen-presenting cells of the immune system, DCs serve as a bridge between innate and adaptive immunity. By impairing DC functions, M. tuberculosis prevents optimal cross talk between DCs and CD4+ T cells and shapes T cell responses to its benefit. However, the bacterial factors that contribute to the M. tuberculosis-mediated impairment of DCs are poorly defined.

We previously demonstrated that the M. tuberculosis protein GroEL2, which is a chaperone-like immunomodulatory protein, modulates macrophage proinflammatory responses. While those studies focused on the role of the full-length (FL) GroEL2 protein, our data suggest that a cleaved form of GroEL2 (GroEL2(cl)) predominates in wild-type M. tuberculosis and that the cleavage of GroEL2 serves to dampen innate immune responses to M. tuberculosis infection. We showed that the FL GroEL2 protein has a multimeric conformation, is exported to the cell wall of M. tuberculosis, and is...
secreted extracellularly (7). In wild-type *M. tuberculosis*, FL GroEL2 is proteolytically cleaved at its N terminus between amino acid residues Arg12 and Gly13 by the serine protease Hip1 into a smaller form, GroEL2(cl), that has a monomeric conformation (7). Cleavage of GroEL2 does not occur in the absence of Hip1 protease activity, and an *M. tuberculosis* hip1 mutant harbors the FL GroEL2 but not the GroEL2(cl) protein. Moreover, the *hip1* mutant induced significantly higher levels of proinflammatory cytokines than did wild-type *M. tuberculosis* during macrophage infection. This was attributed in part to the enhanced immunostimulatory effect of FL GroEL2 on the *hip1* mutant compared to GroEL2(cl), which predominates in wild-type *M. tuberculosis*. The immunomodulatory effects of GroEL2 on macrophage functions suggest that GroEL2 may also play a role in modulating DCs and downstream T cell responses. Therefore, we sought to investigate whether the cleavage of GroEL2 impacts DC functions. We hypothesized that the FL GroEL2 and GroEL2(cl) proteins would differentially impact DC functions and thereby shape the type of antigen-specific T cell responses elicited during infection with *M. tuberculosis*. We show that FL GroEL2, but not cleaved GroEL2, induced robust proinflammatory cytokines from DCs and significantly greater expression of the costimulatory molecules CD40 and CD86 on DCs. We also show that FL GroEL2 promoted efficient antigen presentation and polarization of antigen-specific CD4+ T cells into T helper (Th) subsets that secreted gamma interferon (IFN-γ), interleukin-2 (IL-2), and IL-17. In contrast, GroEL2(cl) was poorly stimulatory and unable to promote antigen presentation to T cells. Moreover, the expression of GroEL2(cl) within the *hip1* mutant restored T cell responses to levels induced by wild-type *M. tuberculosis* in DC-T cell coculture assays. Our studies suggest that the Hip1-mediated cleavage of GroEL2 compromises the ability of DCs to initiate optimal antigen-specific T cell responses, thus dampening the host response to infection.

**RESULTS**

**Enhanced maturation of DCs by FL GroEL2 compared to GroEL2(cl).** At sites of infection, immature DCs undergo maturation upon contact with antigens; mature DCs are characterized by high surface expression levels of costimulatory molecules such as CD40 and CD86, which interact with ligands on T cells to optimally induce T cell activation. To investigate how proteolytic cleavage alters the immunostimulatory capacity of the GroEL2 protein, we first compared the abilities of the purified recombinant FL GroEL2 and GroEL2(cl) proteins to induce the cell surface expression of key costimulatory molecules on DCs (Fig. 1). Recombinant proteins were generated as described previously (7), and endotoxin levels in these protein preparations were determined to be below detection levels (data not shown). We exposed bone marrow-derived DCs (BMDCs) from C57BL/6 mice to either FL GroEL2 or GroEL2(cl) and measured the expression levels of CD40, CD86, and major histocompatibility complex (MHC) class II on the cell surface by flow cytometry. FL GroEL2 induced the robust expression of CD40 and CD86 (Fig. 1); in contrast, GroEL2(cl) induced significantly lower levels of these two markers. Under these conditions, neither form of GroEL2 induced the further expression of MHC class II above baseline levels (data not shown). Overall, these data indicate that the cleavage of GroEL2 blunts its capacity to induce the maturation of DCs.

**Cleavage of *M. tuberculosis* GroEL2 attenuates its ability to induce cytokine responses in DCs.** As DCs undergo maturation, they produce key proinflammatory cytokines, such as IL-12 and IL-6, that are important for polarizing naive Th cells into Th subsets such as IFN-γ-producing Th1 cells (8). We therefore compared the levels of IL-12p40 and IL-6 induced by the recombinant FL GroEL2 and GroEL2(cl) proteins (Fig. 2). We exposed BMDCs to various concentrations of FL GroEL2 and GroEL2(cl) and measured the levels of IL-12p40 and IL-6 in the supernatants after 24 h. FL GroEL2 induced high levels of both IL-12p40 and IL-6 in DCs at each concentration tested. Cytokine levels induced by the FL protein were comparable to those induced by Pam3CysSerLys4 (Pam3CSK4). In contrast, GroEL2(cl) was unable to induce these two cytokines above background levels at all concentrations of the protein tested. We did not detect IL-10,
tumor necrosis factor alpha (TNF-α), or IL-1β production under the conditions tested (data not shown). These data indicate that FL GroEL2 has the capacity to induce proinflammatory cytokine production in DCs but that Hip1-mediated cleavage of GroEL2 abrogates its immunostimulatory capacity.

We next investigated whether the Hip1-dependent cleavage of GroEL2 contributes to impaired DC functions during infection in the context of live wild-type and hip1 mutant M. tuberculosis strains. As shown in Fig. 3A, the hip1 mutant, which harbors only FL GroEL2, induced higher levels of the IL-6 and IL-12 cytokines in infected BMDCs than those induced by wild-type M. tuberculosis (Fig. 3) (9). Complementation of the hip1 mutant with Hip1 (hip1 comp) restored wild-type levels of these cytokines (Fig. 3A). To assess the contribution of GroEL2 cleavage to the hip1 mutant phenotype, we used an

![Graph showing expression of costimulatory molecules CD40 and CD86 on DCs in response to full-length GroEL2 and GroEL2(cl).](image1)

**FIG 1** Expression of costimulatory molecules CD40 and CD86 on DCs in response to full-length GroEL2 and GroEL2(cl). We stimulated C57BL/6 BMDCs with recombinant GroEL2 or GroEL2(cl) for 24 h and analyzed the cell surface expression of CD40 and CD86. Representative histograms and mean fluorescence intensity values for the CD11c⁺ DC subpopulation are shown. Isotype and Pam3CSK4 controls are shown as gray and green outlines, respectively. Data are shown as means ± SD of results of one representative experiment from three independent experiments.

![Graph showing differential stimulation of proinflammatory cytokines from dendritic cells by GroEL2 and GroEL2(cl).](image2)

**FIG 2** Differential stimulation of proinflammatory cytokines from dendritic cells by GroEL2 and GroEL2(cl). We measured levels of the IL-6 and IL-12p40 cytokines produced by C57BL/6 BMDCs 24 h after stimulation with various levels of recombinant GroEL2 or GroEL2(cl). Data are shown as means ± SD of results from one representative experiment of three independent experiments.
engineered hip1 mutant strain that ectopically expressed secreted GroEL2(cl). We previously confirmed that the levels of GroEL2(cl) in the supernatant fraction of the hip1 mutant-GroEL2(cl) strain were comparable to those of wild-type M. tuberculosis (7). Importantly, the expression of GroEL2(cl) in the hip1 mutant background restored wild-type levels of IL-12p40 and IL-6 in infected BMDCs, comparable to the levels seen in the hip1 comp strain. These data suggest that the cleavage of GroEL2 in wild-type M. tuberculosis dampens DC cytokine responses. To more directly assess the immunomodulatory capacity of GroEL2(cl), we compared the effects of exposing BMDCs to both GroEL2(cl) and FL GroEL2 together. We found that the levels of cytokines induced by a 1:1 molar ratio of GroEL2 and GroEL2(cl) in combination were lower than those with the additive effect of each individual protein (Fig. 3B). Together, data from these studies suggest that GroEL2(cl) is capable of dampening the stimulatory effect of FL GroEL2.

**FL GroEL2, but not GroEL2(cl), augments antigen-specific T cell responses.** Based on our observation of the differential production of proinflammatory cytokines and expression of costimulatory markers by DCs in response to GroEL2 and GroEL2(cl), we sought to test whether the cleavage of GroEL2 impacted DC antigen presentation to naive antigen-specific CD4⁺ T cells. We used an in vitro antigen presentation assay involving the coculture of DCs with CD4⁺ T cells isolated from OT-II mice, which are T cell receptor-transgenic (TCR-Tg) mice, specific for the ovalbumin peptide spanning residues 323 to 339 (OVA323–339 peptide). We first pulsed BMDCs with the OVA323–339 peptide and then exposed DCs to FL GroEL2 or GroEL2(cl) for 24 h. We then cocultured BMDCs with OT-II TCR-Tg CD4⁺ T cells, collected supernatants 72 h after coculture, and assayed the cells for IFN-γ, IL-2, and IL-17 by an enzyme-linked immunosorbent assay (ELISA) (Fig. 4A). FL GroEL2 but not GroEL2(cl) stimulated the robust presentation of the OVA323–339 peptide, as assessed by the production of IL-2. Furthermore, DCs stimulated with FL GroEL2 induced significantly higher levels of IFN-γ and IL-17 than those for BMDCs stimulated with GroEL2(cl). Thus, FL GroEL2 enhanced the capacity of BMDCs both to present antigens to CD4⁺ T cells and to induce Th1 and Th17 cytokines, consistent with the enhanced levels of IL-12p40 and IL-6 produced by BMDCs exposed to FL GroEL2. In contrast, BMDCs stimulated with GroEL2(cl), which predominates during M. tuberculosis infection, activated CD4⁺ T cells poorly. Overall, these results suggest that the cleavage of GroEL2 contributes to the modulation of DC-T cell cross talk during M. tuberculosis infection.

To further investigate whether GroEL2(cl) modulates antigen-specific T cell responses during live M. tuberculosis infection, we used DC-T cell coculture assays to assess the production of Th1 and Th17 cytokines. We infected BMDCs with wild-type,
hip1 mutant, and hip1 mutant-GroEL2(cl) M. tuberculosis strains. To assess the ability of DCs infected with each of these strains to polarize naive M. tuberculosis-specific CD4 T cells toward Th1 and Th17 subsets, we cocultured infected BMDCs with purified ESAT-6 TCR-Tg CD4+ T cells (Fig. 4B). Supernatants were harvested 80 h after coculture and assayed for the cytokines IFN-γ, IL-2, and IL-17A by an ELISA. M. tuberculosis hip1 mutant-infected BMDCs induced elevated levels of the IL-17A, IL-2, and IFN-γ cytokines relative to wild-type M. tuberculosis-infected DCs. However, BMDCs infected with the M. tuberculosis hip1 mutant-GroEL2(cl) strain produced significantly lower IL-17A, IL-2, and IFN-γ cytokine levels, comparable to those of BMDCs infected with wild-type M. tuberculosis. Overall, these data suggest that GroEL2(cl) effectively blunts the magnitude of T cell responses during infection and that cleavage of GroEL2 is a strategy employed by M. tuberculosis to modulate DC-T cell cross talk.

**DISCUSSION**

While it is known that M. tuberculosis impairs DC functions, the underlying bacterial mechanisms are poorly defined. In this study, we characterized the contribution of FL and cleaved forms of the M. tuberculosis GroEL2 protein in modulating the DC-T cell interface. While most studies on GroEL2 have focused on the ability of the FL protein to modulate innate immune responses, our studies are the first to show that the cleavage of GroEL2 prevents robust DC activation and impacts cross talk between DC and CD4+ T cells (10–20). Since GroEL2 is present predominantly as a cleaved monomeric protein in wild-type M. tuberculosis, these studies provide new insights into the way in which the cleavage of GroEL2 impacts DC-T cell cross talk. Our studies also extend previous findings in macrophages showing that recombinant
full-length GroEL2 induces proinflammatory cytokines in a Toll-like receptor (TLR)-dependent manner (7, 21).

Using purified recombinant FL and cleaved GroEL2 proteins, we show that the cleavage of GroEL2 abrogates its immunostimulatory capacity toward DCs and significantly limits the production of key cytokine mediators such as IL-12 and IL-6 (Fig. 2). In these in vitro studies, we considered the biological relevance of the amount of GroEL2 used in our experiments. Because the amounts of GroEL2 that are present during infection are not known, we decided to test a range of protein concentrations. Therefore, in our experiments, we show data for molar concentrations of GroEL2 ranging from 0.1 μM to 10 μM. Based on densitometry analysis of Western blot images, we estimate that the concentration of the GroEL2(cl) protein in M. tuberculosis culture supernatants is in the range of 0.1 μM to 1 μM.

To investigate the role of GroEL2 cleavage during M. tuberculosis infection of DCs, we took advantage of M. tuberculosis bacterial strains that predominantly harbored cleaved GroEL2 (wild-type M. tuberculosis and the complemented hip1 mutant), FL GroEL2 (M. tuberculosis hip1 mutant), or a strain that was engineered to express GroEL2(cl) within the hip1 mutant. We found that the ectopic expression of cleaved GroEL2 in the hip1 mutant background significantly diminished the hyper-inflammatory phenotype of the M. tuberculosis hip1 mutant (Fig. 3A). These data suggest that the cleavage of GroEL2 in wild-type M. tuberculosis directly contributes to impaired DC functions during infection and is likely to be a major contributor to the hip1 mutant phenotype. Furthermore, we found that the addition of GroEL2(cl) dampens proinflammatory responses of DCs (Fig. 3B). We also generated a hip1 mutant strain expressing full-length GroEL2, which we wanted to include as an important control. Unfortunately, this strain has a significant in vitro growth defect, suggesting that the presence of high levels of full-length GroEL2 in the hip1 mutant strain is not well tolerated. Because of this growth defect, we were unable to include this strain in our in vitro assays.

The differential functions of GroEL2 and GroEL2(cl) are reminiscent of data from studies on other immunostimulatory heat shock family proteins. Fong et al. reported that heat shock protein 70 (Hsp70), similarly to GroEL2(cl), is secreted from cells and is capable of activating the immunomodulatory Siglec receptors on monocytes and neutrophils (22). Intriguingly, Hsp70 delivers both anti-inflammatory and proinflammatory signals through Siglec activation, pointing to important functional polymorphisms of extracellular Hsp proteins. In the context of these findings, our own data suggest that the two forms of M. tuberculosis GroEL2 are likely to be functionally distinct and that the balance between the amounts of the two forms of GroEL2 during DC infection will influence the type of host immune response generated. We also show that FL GroEL2, but not GroEL2(cl), leads to an upregulation of cell surface-associated costimulatory molecules on DCs such as CD40 and CD86 (Fig. 1) and elicits significantly higher levels of IFN-γ, IL-2, and IL-17 from antigen-specific CD4+ T cells (Fig. 4A). Furthermore, in the context of live infection, during DC-T cell coculture, GroEL2(cl) modulates antigen-specific T cell responses and thus promotes suboptimal immune responses (Fig. 4B). These results are consistent with data from previous reports on the ability of FL M. tuberculosis GroEL2 to enhance antigen cross-presentation during DC-T cell coculture (10). Furthermore, data from biochemical and structural studies indicate that GroEL2 may be involved in promoting antigen presentation. GroEL2 possesses specific protein domains that have the potential to bind peptide substrates, a process that likely facilitates their subsequent association with MHC molecules (23, 24). Together, our results highlight GroEL2 cleavage as a mechanism employed by M. tuberculosis to modulate DC-mediated immunity during infection.

Our studies add insight to a growing body of data implicating GroEL2 in modulating host immune responses to M. tuberculosis infection. Mycobacteria are unusual among bacteria in possessing two GroEL proteins, the cytoplasmic protein GroEL1, which is highly homologous to the Escherichia coli GroEL chaperonin, and GroEL2 (25, 26). While
GroEL2 is cytoplasmic, GroEL2 is localized to the cell envelope and secreted extracellularly. Interestingly, GroEL2 has been reported to be among the most abundant \textit{M. tuberculosis} proteins \textit{in vivo} and a dominant contributor to the potent immune response elicited by \textit{M. tuberculosis} purified protein derivative (PPD) (27, 28). Indeed, several studies investigated GroEL2 as a vaccine adjuvant, showing that FL GroEL2 boosts the magnitude of the immune response against infection, thereby improving vaccine-mediated protection against \textit{M. tuberculosis} (17–20). Those studies show that FL GroEL2 appears to mediate its efficacy via a cellular response dominated by IFN-\gamma-producing Th1 cells (18). Our results on the functional differences between FL GroEL2 and cleaved GroEL2 add credence to these findings and highlight a potential use for GroEL2 as an immunomodulatory component in strategies aimed at improving vaccine-induced immunity to \textit{M. tuberculosis} infection.

\section*{MATERIALS AND METHODS}

\textbf{Plasmid construction.} (i) Plasmids for expression in \textit{E. coli}. \textit{M. tuberculosis} groEL2 was cloned into pACYCDuet-1 (Merck Millipore, Darmstadt, Germany) via the restriction sites EcoRI and KpnI by using the InFusion cloning system according to the manufacturer’s protocol. \textit{M. tuberculosis} groEL2 was amplified by using the primers 5'-GCCAGATTCGGGCCTCGAGCGGGGCTTGAACGCC-3' and 5'-TTACCGAGCTCACGAGCTGGGCTTGAACGCC-3', yielding a construct bearing an in-frame N-terminal 6\times His tag and a C-terminal S-tag, yielding pACYCDuet-1 GroEL2. Using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, we previously identified GroEL2 as being cleaved between amino acid positions 12 and 13 at the N terminus to produce the cleaved GroEL2 protein (7). Using this information, we constructed \textit{M. tuberculosis} groEL2(cl) by using primers 5'-TCCACGGGAATTCGGCCCTCGAGCCGAGTGAATTCTCAGACCTGGTAA-3' and 5'-TCCAGTGGTACCTCGAGCCGAGTGAATTCTCAGACCTGGTAA-3', yielding a pAECDuet-1 GroEL2(cl) construct bearing an in-frame N-terminal 6\times His tag and a C-terminal S-tag.

(ii) Plasmids for expression in \textit{M. tuberculosis}: secreted GroEL2(cl)-Myc. To express the cleaved form of GroEL2, GroEL2(cl), the groEL2 gene (minus the first 13 amino acids) was amplified from the \textit{M. tuberculosis} genome by using forward primer 5'-AGCGAGCTGGGCTCAGACCTGGTAA-3' and reverse primer 5'-AGTAAGCTTTCACAGATCTTCTTCAGAAATAAGTTTTTGTTCGAAATCCATGCCACCCATG-3', and cloned into the PvuII and HindIII sites of pmMV762, downstream of the predicted N-terminal signal sequence from \textit{M. tuberculosis} antigen 85 complex B (NH2-MTDYSRKRIRAVGRRLMGAAVAVLVPGLVLGLAG GAATAGA-OH) and an in-frame C-terminal Myc tag.

\textbf{Expression and preparation of recombinant proteins GroEL2 and GroEL2(cl) from \textit{E. coli}.} Plasmids pACYCDuet-1 GroEL2 and pACYCDuet-1 GroEL2(cl) were separately transformed into \textit{E. coli} BL21 Star(DE3) (Invitrogen, Carlsbad, CA) for protein expression. LB broth (1 liter) containing 34 \mu g/ml chloramphenicol was inoculated with 5 ml of a culture grown overnight and incubated at 37°C to an optical density at 600 nm (OD600) of 0.6 to 0.8. The cells were cooled to room temperature for 15 to 30 min, after which 1 ml isopropyl-\beta-D-thiogalactopyranoside (IPTG) was added, and the cells were incubated overnight at 28°C. The cells were then centrifuged at 10,000 rpm for 1 h. The cell pellet containing GroEL2 or GroEL2(cl) was resuspended in binding buffer (20 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole [pH 7.9], 200 \mu g/ml lysozyme, 1.8 \mu g/\mu l DNase) plus a protease inhibitor cocktail (Santa Cruz Biotechnology, Dallas, TX), sonicated, and centrifuged at 16,000 \times g for 90 min to remove cellular debris and clarify the mixture. The soluble fraction was added to Ni\textsuperscript{2+}-charged beads in a gravity column. The cell lysate in the gravity column was first washed with wash buffer 1 (20 mM Tris-HCl, 500 mM NaCl, 60 mM imidazole [pH 7.9]) and then washed with wash buffer 2 (10 mM Tris-HCl) to remove residual salts from the column. To remove endotoxin, the cell lysate was washed with 0.5% ASB-14 (Millipore, Billerica, MA) in 10 mM Tris-HCl. Finally, the lysate was washed with 10 mM Tris-HCl to remove any excess detergent. The protein was eluted with 1 M imidazole in 10 mM Tris-HCl and dialyzed overnight in 1 \times phosphate-buffered saline (PBS). The protein was further purified by size exclusion chromatography on a GE Superdex 75 10/300 GL column. The purified protein was then concentrated. The endotoxin levels for each protein were <10 ng/ml, as determined by using a \textit{Limulus} amoebocyte lysate (LAL) chromogenic endotoxin quantitation kit (Thermo Scientific, Rockford, IL). Proteins were subjected to SDS-PAGE and visualized as a single band by staining with 0.05% Coomassie blue R-250. The concentrations of purified proteins were determined by the Bradford method (29), using bovine serum albumin (BSA) as the standard.

\textbf{Bacterial strains and media.} \textit{M. tuberculosis} H37Rv, the \textit{hip} mutant strain (described previously) (30, 31), and the \textit{M. tuberculosis} strain expressing GroEL2(cl) were grown at 37°C in Middlebrook 7H9 broth or 7H10 medium supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC) (Becton Dickinson, Franklin Lakes, NJ), 0.02% glycerol, and 0.05% Tween 80 (for broth), with the addition of 25 \mu g/ml kanamycin (Sigma-Aldrich, St. Louis, MO) for the \textit{hip} mutant, and for complemented strains, 10 \mu g/ml streptomycin (Sigma-Aldrich, St. Louis, MO) or 50 \mu g/ml hygromycin (Roche Diagnostics, Indianapolis, IN) was added.

\textbf{Mice.} All mice were housed under specific-pathogen-free conditions in filter-top cages within the vivarium at the Yerkes National Primate Center, Emory University, and provided with sterile water and food \textit{ad libitum}. C57BL/6 mice were purchased from The Jackson Laboratory, OT-Il-Tg mice specific for
the OVA323-339 peptide, originally generated in the laboratory of F. Carbone (University of Melbourne, Melbourne, Vic, Australia), were bred at the Yerkes animal facility.

**Dendritic cells and cytokine assays.** For generating murine BMDCs, bone marrow cells from C57BL/6 mice were flushed from excised femurs and tibias and grown in RPMI 1640 medium (Lonza, Walkersville, MD) with 10% heat-inactivated fetal bovine serum (FBS) (HyClone, Logan, UT), 2 mM glutamine, 13 μM 2-mercaptoethanol (2-ME), 10 mM HEPES, 1 mM sodium pyruvate, 13 nonessential amino acids, and 20 ng/ml murine recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) (R&D Systems, Minneapolis, MN). Incubations were carried out at 37°C with 5% CO₂. Fresh medium with GM-CSF was added on days 3 and 6, and cells were used on day 7 for all experiments. We routinely obtained ~75% CD11c⁺ CD11b⁺ cell purity by flow cytometry. BMDCs were further purified by using magnetic beads coupled to a CD11c⁺ monoclonal antibody (MAB) and passed through an AutoMACS column according to the manufacturer’s instructions, where indicated (Miltenyi Biotec, Auburn, CA). For all experiments, cells were maintained in medium containing GM-CSF.

For infection, BMDCs were plated onto 24-well plates (3 × 10⁶ cells per well). Bacteria were filtered through 5-μm filters, resuspended in complete medium containing 20 ng/ml GM-CSF, and sonicated twice for 5 s each before addition to the adherent monolayers. Each bacterial strain was used for infection (in duplicate or triplicate) at a multiplicity of infection (MOI) of 5 or as indicated. Infection of BMDCs was carried out for 4 h, after which monolayers were washed four times with PBS before replacement with RPMI 1640 medium containing 20 ng/ml GM-CSF. To determine intracellular CFU, one set of DCs was lysed in PBS containing 0.5% Triton X-100 and plated onto 7H10 agar plates containing the appropriate antibiotics.

For stimulation of BMDCs with the recombinant GroEL2 protein, endotoxin-free GroEL2 and GroEL2(cl) in supplemented RPMI 1640 medium (as described above) were added to C57BL/6 BMDCs for 24 h. Cell-free supernatants from DC monolayers were isolated at the indicated points and assayed for cytokines by an ELISA using Duo Set kits for IL-12p40, IL-6, and IL-10 (BD Biosciences, San Jose, CA). Assays were carried out according to the manufacturer’s instructions. Uninfected BMDCs were used as controls for each experiment.

**DC–T cell coculture assays.** (i) **Live M. tuberculosis strains.** BMDCs were differentiated and plated as described above. BMDCs were infected (in triplicate) with wild-type, hip1 mutant, or hip1 mutant GroEL2(cl) M. tuberculosis strains at an MOI of 10. Infection of BMDCs was carried out for 4 h, after which monolayers were incubated with amikacin (200 μg/ml; Sigma-Aldrich) for 45 min to kill extracellular bacteria and then washed four times with PBS before incubation for 24 h in complete medium. Following washing, to determine intracellular CFU, one set of DCs was lysed in PBS containing 0.5% Triton X-100 and plated on 7H10 agar plates containing the appropriate antibiotics. On the following day, BMDCs were cocultured with ESAT-6-specific TCR-Tg CD4⁺ T cells at a 1:4 DC:T cell ratio for 80 h. CD4⁺ T cells were purified from single-cell suspensions of spleen and lymph nodes from 6- to 8-week-old transgenic mice by using a MACS Miltenyi M1/70) were obtained from BioLegend, and anti-CD40 phycoerythrin (PE) (clone M5/114.15.2) were purchased from BD Biosciences. Staining for cell surface markers was done by resuspending

**Flow cytometry.** Murine anti-CD11c allophycocyanin (clone N418) and anti-CD11b fluorescein isothiocyanate (FITC) (clone M1/70) were obtained from BioLegend, and anti-CD40 phycoerythrin (PE) (clone 23/123), anti-CD86 PE (clone GL1), and anti-MHC class II PE (clone MS/114.15.2) were purchased from BD Biosciences. Staining for cell surface markers was done by resuspending ~1 × 10⁶ cells in 200 ml PBS with 2% FBS containing the antibody mixture. Cells were incubated at 4°C for 30 min and then washed with PBS containing 2% FBS. Data were immediately acquired by using an LSR flow cytometer (BD Biosciences). Data were analyzed with FlowJo software (Tree Star, San Carlos, CA).

**Statistical analysis.** The statistical significance of data was analyzed by using Student’s unpaired t test (GraphPad Prism 5.0a) (*, P < 0.05; **, P < 0.01; ***, P < 0.0002; ****, P < 0.0001). Data are shown as means ± standard deviations (SD) of data from one representative experiment from three independent experiments.

**ACKNOWLEDGMENTS**

This work was supported by grants 5R01AI083366-05 and 2R56AI083366-06A1 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (to J.R.); Yerkes National Primate Center base grant RR000165, and Center for AIDS Research (CFAR) Immunology Core grant P30AI050409 (to Emory University).

J.R., M.G., J.K.S., E.B., and R.M.-L. conceived and designed the experiments. M.G., J.K.S., E.B., and R.M.-L. performed the experiments. J.R., M.G., J.K.S., and E.B. analyzed the...
REFERENCES


